GLP-1s in the Dominican Republic: On the Essential Medicines List, Still Not Covered by Insurers
More than a year after entering the country's essential medicines list, GLP-1 treatments for obesity and diabetes still lack effective ARS (health insurer) coverage. The science is here; access is not.
The news
On August 22, Diario Libre reported that innovative obesity and diabetes medications — GLP-1 agonists like semaglutide, SGLT-2 inhibitors, and high-intensity statins — were added to the Dominican Republic's essential medicines list more than a year ago, yet still lack effective coverage from the ARS (the country's health insurers).
Dr. Dolores Mejía, endocrinologist and president of the Diabetes Observatory, summed it up: more than a year has passed without coverage being implemented in practice; the country must "move from paper to practice." Treating obesity, she said, is "a country necessity."
The scale of the problem in the DR
The context explains the urgency: roughly 68% of the Dominican population lives with overweight or obesity, and the trend is rising. Meanwhile, the full GLP-1 class is arriving in the local market — tirzepatide is already sold in the country through formal pharmaceutical channels.
The problem is the wallet: without ARS coverage, these treatments are paid fully out of pocket — a monthly cost out of reach for most patients who need them. Per data cited by the Observatory, one in three semaglutide users achieves reductions of up to 25% of body weight — benefits currently reserved for those who can afford them.
What's missing for coverage
The bottleneck is institutional: inclusion on the essential medicines list recognizes these medications "on paper," but real coverage requires the National Social Security Council (CNSS) to authorize the ARS to cover them. Until that authorization arrives, the gap between approved and accessible remains.
What it means
For patients, the path doesn't change: doctor, pharmacy, and the formal healthcare system. Nothing substitutes for that, and public pressure for coverage — like the Diabetes Observatory's — is the route to closing the gap.
For the research community, the reading is different: interest in incretin biology in the country has never been higher, and understanding how these mechanisms work is the starting point. Our technical guides cover the foundation: how GLP-1 agonists work (GLP-1, GIP, glucagon — three hormones, three receptors) and the technical comparison between dual and triple agonists with published SURMOUNT and TRIUMPH data.
The material Renova distributes is research use only (RUO): it is not medication, does not substitute for any prescribed treatment, and is not fit for human or veterinary consumption. If the topic is clinical treatment, the route is your doctor and the formal healthcare system.
Sources
⚠ Research use only. Not medical advice.